The first China clinical trial using human embryonic stem (ES) cells will soon get underway. Zhengzhou University researchers in Henan Province plan to implant four million neuronal-precursor cells, developed from embryonic stem cells, into the brains of patients with Parkinson’s disease. The goal will be to address the dopamine deficit that causes Parkinson’s. The test will be the first China clinical trial of ES cells since 2015, when China adopted new rules to regulate stem cell experimentation and outlaw unproven stem cell treatments.
